🇺🇸 FDA
Patent

US 10093664

Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease

granted A61PA61P25/00A61P25/02

Quick answer

US patent 10093664 (Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease) held by The Board of Regents of the University of Texas System expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P25/00, A61P25/02, A61P25/04, A61P25/14